TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501 ...

Sorrento Therapeutics faced a financial and legal crisis in February 2023, and needed to file for bankruptcy. The pharmaceutical developer’s chief executive and chief financial officers met with ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Viking Therapeutics stock has already tripled in 2024, but Wall Street analysts think it has more room to run. Viking Therapeutics' lead candidate is an experimental weight management treatment ...

Travere Therapeutics' stock has been volatile due to Filspari's failed Phase 3 trials, but a full FDA approval is possible next week that could boost its share price. Despite setbacks, Filspari's ...

A digital therapeutic (DTx) is defined as “health software intended to treat or alleviate a disease, disorder, condition, or injury by generating and delivering a medical intervention that has a ...

Travere Therapeutics (TVTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Liisa Bayko from Evercore ISI maintained a Buy rating on the ...

Therapeutics are treatments used to alleviate or prevent a particular disease. Examples of therapeutics include drug therapy, medical devices, nutrition therapy and stem-cell therapies ...

Rubius Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, USA, that is developing allogeneic cell therapies based on biologically engineered red blood cells (RBCs).

We came across a bullish thesis on TG Therapeutics Inc (TGTX) on ValueInvestorsClub by Bohr. In this article we will summarize the bulls' thesis on TGTX. TG Therapeutics shares were trading at $14 ...

Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, shows promising results in Phase II trials for obesity treatment with potential for both subcutaneous and oral formulations.

PRINCETON, N.J., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (“Agile”) (OTCQB: AGRX), a women's healthcare company, today announced the completion of the acquisition of Agile by ...